Breakthroughs in understanding and treating eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERs Symposium at the 2022 American Academy of Allergy, Asthma & Immunology Meeting

J Allergy Clin Immunol. 2023 Dec;152(6):1382-1393. doi: 10.1016/j.jaci.2023.08.021. Epub 2023 Sep 3.


The Consortium of Eosinophilic Gastrointestinal Diseases and The International Gastrointestinal Eosinophil Researchers organized a day-long symposium at the 2022 Annual Meeting of the American Academy of Allergy, Asthma & Immunology. The symposium featured a review of recent discoveries in the basic biology and pathogenesis of eosinophilic gastrointestinal diseases (EGIDs) in addition to advances in our understanding of the clinical features of EGIDs. Diagnostic and management approaches were reviewed and debated, and clinical trials of emerging therapies were highlighted. Herein, we briefly summarize the breakthrough discoveries in EGIDs.

Keywords: Eosinophilic esophagitis; eosinophil; eosinophilic gastritis; food allergy.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asthma* / diagnosis
  • Asthma* / therapy
  • Enteritis* / diagnosis
  • Enteritis* / therapy
  • Eosinophilia*
  • Eosinophilic Esophagitis*
  • Gastritis*
  • Humans
  • United States

Supplementary concepts

  • Eosinophilic enteropathy